TIL therapy shows promise with gentler prep
IOVA reported that Amtagvi, a tumor‑infiltrating lymphocyte (TIL) therapy, showed efficacy in high‑risk melanoma even with reduced lymphodepletion — meaning patients could need less aggressive preconditioning. If confirmed, that could expand access to TIL treatments by lowering the intensity and risk of the preparation regimen. That outcome is a concrete example of how clinical innovation sits at the clinical‑biotech interface, affecting trial design and patient care pathways. (x.com)
Tumor-infiltrating lymphocyte therapy starts with a strange idea: the best cancer-fighting cells may already be hiding inside the tumor, and doctors can cut them out, grow billions more in a lab, and send them back in one infusion. The Food and Drug Administration approved Iovance’s lifileucel, sold as Amtagvi, on February 16, 2024, as the first cell therapy for a solid tumor. (cancer.gov) (fda.gov) Before those cells go back in, patients usually get lymphodepleting chemotherapy, which clears space in the immune system the way gardeners pull weeds before planting. The standard lifileucel regimen has used nonmyeloablative lymphodepletion followed by the cell infusion and then up to 6 doses of high-dose interleukin-2, an immune-boosting drug. (cancer.gov) (iovance.com) That prep work is one reason TIL therapy has been hard to deliver outside specialized centers. The National Cancer Institute noted in 2024 that the treatment requires tumor surgery, off-site manufacturing, lymphodepleting chemotherapy, and hospital-based follow-up after infusion. (cancer.gov) Now the new wrinkle: a Moffitt Cancer Center study looked at whether some high-risk melanoma patients could get a lighter version of that chemotherapy without losing the treatment effect. The study used the commercial lifileucel product in 17 patients with advanced melanoma and cut cyclophosphamide in half, from 60 mg/kg/day to 30 mg/kg/day for 2 days, while keeping fludarabine at 25 mg/m²/day for 5 days. (targetedonc.com) (astctjournal.org) These were not easy cases. The eligibility rules targeted frailty markers including age 70 or older, recently treated brain metastases, bowel bleeding or bowel metastases, recent deep vein thrombosis on blood thinners, or coronary artery disease with a recent coronary stent procedure requiring antiplatelet drugs. (targetedonc.com) Among 16 evaluable patients, the objective response rate was 44%, meaning 7 patients had confirmed partial responses. At 12 months, progression-free survival was 38% and overall survival was 61%, which the investigators described as broadly comparable to the pivotal lifileucel data used for approval. (targetedonc.com) (astctjournal.org) The safety signal is why oncologists are paying attention. Grade 3 thrombocytopenia occurred in 47% of patients, febrile neutropenia in 59%, median hospitalization was 14 days, and there were no deaths within 30 days in this series. (targetedonc.com) Even with the lower cyclophosphamide dose, all patients still reached the intended grade 4 lymphopenia, which is the deep immune-cell dip doctors want before the infused cells expand. Median neutrophil recovery was 7 days, and 94% of patients had platelet recovery by day 30. (targetedonc.com) This does not change the label today. Amtagvi is still approved under accelerated approval for adults with unresectable or metastatic melanoma after a programmed cell death protein 1 blocker and, for BRAF V600-mutant disease, a BRAF-targeted regimen, and the Food and Drug Administration says confirmatory evidence is still required. (fda.gov) The approved trial that got lifileucel over the line was smaller on response than many cancer headlines suggest. In the registrational C-144-01 study, the objective response rate was 31.4%, and a 5-year analysis presented in 2025 reported that about 20% of treated patients were still alive at 5 years. (iovance.com) So the real story is not that TIL therapy suddenly became easy. It is that one of the hardest parts of the regimen may be adjustable, and if prospective trials confirm that, more older or medically fragile melanoma patients could become eligible for a treatment that used to demand a tougher runway. (targetedonc.com) (clinicaltrials.gov)
